Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Фазлодекс: новые возможности эндокринотерапии рака молочной железы
Фазлодекс: новые возможности эндокринотерапии рака молочной железы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье представлены данные, касающиеся различных направлений применения Фазлодекса как в адъювантной, так и в неоадъювантной эндокринотерапии гормонопозитивного рака молочной железы. Определены современные тенденции практического применения уникального механизма действия данной лекарственной формы, способной реально повысить эффективность системной терапии. Показаны перспективы комбинаций Фазлодекса с различными препаратами молекулярно направленного действия.
Ключевые слова: рак молочной железы, Фазлодекс, адъювантная эндокринотерапия, неоадъювантная эндокринотерапия.
Key words: breast cancer, Fazlodex, adjuvant endocrinotherapy, neoadjuvant endocrinotherapy.
Ключевые слова: рак молочной железы, Фазлодекс, адъювантная эндокринотерапия, неоадъювантная эндокринотерапия.
________________________________________________
Key words: breast cancer, Fazlodex, adjuvant endocrinotherapy, neoadjuvant endocrinotherapy.
Полный текст
Список литературы
1. Parker MG. Action of pure antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993; 26: 131–7.
2. Dauvois S, White R, Parker MG. The antiestrogen ICI182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106 (4): 1377–88.
3. Bross P, Baird A, Chen G et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003; 9: 4309–17.
4. Shim WS, Conaway M, Masamura S et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000; 141: 396–405.
5. Chan CM, Martin LA, Johnston SR et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002; 81: 333–41.
6. Martin LA, Farmer I, Johnston SRD et al. Enhanced estrogen receptor (ER) a, ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003; 278: 30458–68.
7. Jeng MH, Shupnik MA, Bender TP et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology.
8. Howell A. Critical Reviews in Oncology Hematology 2006; 57: 265–73.
9. Steger G, Bartsch R, Wenzel C et al. Fulvestrant (Faslodex®) in metastatic breast cancer. Breast Cancer Res Treat 2003; 82 (Suppl. 1): 104. Abstr. 437.
10. Howell A, Robertson JF, Quaresma AJ et al. Fulvestrant, formerly ICI182780 is as effective as Anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396–403.
11. Ingle JN, Rowland KM, Suman VJ et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 2004; 88 (Suppl. 1): 38. Abstr 409.
12. Perey L, Paridaens R, Nol F et al. Fulvestrant (Faslodex‰) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 2004; 88 (Suppl. 1): 6048. Abstr. 236.
13. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational double-blind randomized trial. J Clin Oncol 2004; 22: 1605–13.
14. Robertson JF, Nicholson RI, Bundred NJ et al. Comparison of the short-term biological effects of 7-alpha-9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl.estra-1,3,5(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 61: 6739–46.
15. Osborne CK, Pippen J, Jones SE et al. Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386–95.
16. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746–50.
17. Robertson JF, Howell A, Gorbunova VA et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005; 92 (2): 169–74.
18. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98 (2): 229–38.
19. Agraval A, Hannon RA, Cheung KL et al. Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. ASCO 2006. Abstr. 680.
20. Steger G, Bartsch R, Wenzel C et al. Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer: A pilot study. J Clin Oncol 2005; 23: 55. Abstr. 708.
21. Bauerschlag DO, Schem C, Jonat W et al. University of Schleswig-Holstein, Kiel, Germany. Clinical experience using fulvestrant in hormone responsive metastatic breast cancer. ASCO 2006. Abstr. 10749.
22. Petruzelka L, Zimovjanova M, Konopasek B et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy – updated results from an expanded access programme. Ann Oncol 2004; 15 (Suppl. 3): 136. Abstr. 36.
23. Piccart-Gebhart MJ, Loi SM. Fulvestrant – ready to start its journey in the breast cancer adjuvant endocrine world. Eur J Cancer 2005; 41: 341–3.
24. Robertson JFR, Semiglazov V, Gee JM, Armstrong J. Effects of fulvestrant in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer 2004; (Suppl. 2): 73. Abstr. 59.
2. Dauvois S, White R, Parker MG. The antiestrogen ICI182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106 (4): 1377–88.
3. Bross P, Baird A, Chen G et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003; 9: 4309–17.
4. Shim WS, Conaway M, Masamura S et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000; 141: 396–405.
5. Chan CM, Martin LA, Johnston SR et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002; 81: 333–41.
6. Martin LA, Farmer I, Johnston SRD et al. Enhanced estrogen receptor (ER) a, ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003; 278: 30458–68.
7. Jeng MH, Shupnik MA, Bender TP et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology.
8. Howell A. Critical Reviews in Oncology Hematology 2006; 57: 265–73.
9. Steger G, Bartsch R, Wenzel C et al. Fulvestrant (Faslodex®) in metastatic breast cancer. Breast Cancer Res Treat 2003; 82 (Suppl. 1): 104. Abstr. 437.
10. Howell A, Robertson JF, Quaresma AJ et al. Fulvestrant, formerly ICI182780 is as effective as Anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396–403.
11. Ingle JN, Rowland KM, Suman VJ et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 2004; 88 (Suppl. 1): 38. Abstr 409.
12. Perey L, Paridaens R, Nol F et al. Fulvestrant (Faslodex‰) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 2004; 88 (Suppl. 1): 6048. Abstr. 236.
13. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational double-blind randomized trial. J Clin Oncol 2004; 22: 1605–13.
14. Robertson JF, Nicholson RI, Bundred NJ et al. Comparison of the short-term biological effects of 7-alpha-9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl.estra-1,3,5(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 61: 6739–46.
15. Osborne CK, Pippen J, Jones SE et al. Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386–95.
16. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746–50.
17. Robertson JF, Howell A, Gorbunova VA et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005; 92 (2): 169–74.
18. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98 (2): 229–38.
19. Agraval A, Hannon RA, Cheung KL et al. Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. ASCO 2006. Abstr. 680.
20. Steger G, Bartsch R, Wenzel C et al. Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer: A pilot study. J Clin Oncol 2005; 23: 55. Abstr. 708.
21. Bauerschlag DO, Schem C, Jonat W et al. University of Schleswig-Holstein, Kiel, Germany. Clinical experience using fulvestrant in hormone responsive metastatic breast cancer. ASCO 2006. Abstr. 10749.
22. Petruzelka L, Zimovjanova M, Konopasek B et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy – updated results from an expanded access programme. Ann Oncol 2004; 15 (Suppl. 3): 136. Abstr. 36.
23. Piccart-Gebhart MJ, Loi SM. Fulvestrant – ready to start its journey in the breast cancer adjuvant endocrine world. Eur J Cancer 2005; 41: 341–3.
24. Robertson JFR, Semiglazov V, Gee JM, Armstrong J. Effects of fulvestrant in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer 2004; (Suppl. 2): 73. Abstr. 59.
Авторы
И.В.Высоцкая
Первый МГМУ им. И.М.Сеченова
1st Sechenov Moscow State University for Medicine
Первый МГМУ им. И.М.Сеченова
________________________________________________
1st Sechenov Moscow State University for Medicine
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.